Literature DB >> 35233692

Three cases of Creutzfeldt-Jakob disease presenting with a predominant dysexecutive syndrome.

Nick Corriveau-Lecavalier1, Wentao Li1, Vijay K Ramanan1, Daniel A Drubach1, Gregory S Day2, David T Jones3,4.   

Abstract

Creutzfeldt-Jakob disease (CJD) is a rare, uniformly fatal prion disease. Although CJD commonly presents with rapidly progressive dementia, ataxia, and myoclonus, substantial clinicopathological heterogeneity is observed in clinical practice. Unusual and predominantly cognitive clinical manifestations of CJD mimicking common dementia syndromes are known to pose as an obstacle to early diagnosis and prognosis. We report a series of three patients with probable or definite CJD (one male and two females, ages 52, 58 and 68) who presented to our tertiary behavioral neurology clinic at Mayo Clinic Rochester that met criteria for a newly defined progressive dysexecutive syndrome. Glucose hypometabolism patterns assessed by 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) strongly resembled those of dysexecutive variant of Alzheimer's disease (dAD). However, magnetic resonance imaging (MRI) demonstrated restricted diffusion in neocortical areas and deep nuclei, while cerebrospinal fluid biomarkers indicated abnormal levels of 14-3-3, total-tau, and prion seeding activity (RT-QuIC), establishing the diagnosis of CJD. Electroencephalogram (EEG) additionally revealed features previously documented in atypical cases of CJD. This series of clinical cases demonstrates that CJD can present with a predominantly dysexecutive syndrome and FDG-PET hypometabolism typically seen in dAD. This prompts for the need to integrate information on clinical course with multimodal imaging and fluid biomarkers to provide a precise etiology for dementia syndromes. This has important clinical implications for the diagnosis and prognosis of CJD in the context of emerging clinical characterization of progressive dysexecutive syndromes in neurodegenerative diseases like dAD.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Atypical dementia; Behavioral neurology; Creutzfeldt–Jakob disease; Dysexecutive syndrome; FDG-PET

Mesh:

Substances:

Year:  2022        PMID: 35233692      PMCID: PMC9516260          DOI: 10.1007/s00415-022-11045-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   6.682


  42 in total

1.  Comparison of the Short Test of Mental Status and the Montreal Cognitive Assessment Across the Cognitive Spectrum.

Authors:  Ryan A Townley; Jeremy A Syrjanen; Hugo Botha; Walter K Kremers; Jeremiah A Aakre; Julie A Fields; Mary M Machulda; Jonathan Graff-Radford; Rodolfo Savica; David T Jones; David S Knopman; Ronald C Petersen; Bradley F Boeve
Journal:  Mayo Clin Proc       Date:  2019-07-04       Impact factor: 7.616

2.  A case of Creutzfeldt-Jakob disease presenting with cortical deafness.

Authors:  E Tobias; C Mann; I Bone; R de Silva; J Ironside
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-07       Impact factor: 10.154

3.  A fronto-parietal circuit for object manipulation in man: evidence from an fMRI-study.

Authors:  F Binkofski; G Buccino; S Posse; R J Seitz; G Rizzolatti; H Freund
Journal:  Eur J Neurosci       Date:  1999-09       Impact factor: 3.386

4.  Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimer's disease: a series of clinical cases.

Authors:  Nick Corriveau-Lecavalier; Mary M Machulda; Hugo Botha; Jonathan Graff-Radford; David S Knopman; Val J Lowe; Julie A Fields; Nikki H Stricker; Bradley F Boeve; Clifford R Jack; Ronald C Petersen; David T Jones
Journal:  J Neurol       Date:  2022-02-25       Impact factor: 6.682

5.  Lateralized and focal clinical, EEG, and FLAIR MRI abnormalities in Creutzfeldt-Jakob disease.

Authors:  Denise M Cambier; Kejal Kantarci; Gregory A Worrell; Barbara F Westmoreland; Allen J Aksamit
Journal:  Clin Neurophysiol       Date:  2003-09       Impact factor: 3.708

6.  The short test of mental status. Correlations with standardized psychometric testing.

Authors:  E Kokmen; G E Smith; R C Petersen; E Tangalos; R C Ivnik
Journal:  Arch Neurol       Date:  1991-07

Review 7.  Unusual Clinical Presentations Challenging the Early Clinical Diagnosis of Creutzfeldt-Jakob Disease.

Authors:  Simone Baiardi; Sabina Capellari; Anna Bartoletti Stella; Piero Parchi
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 8.  Cognitive and behavioural flexibility: neural mechanisms and clinical considerations.

Authors:  Lucina Q Uddin
Journal:  Nat Rev Neurosci       Date:  2021-02-03       Impact factor: 34.870

9.  A head-to-head comparison of cerebral blood flow SPECT and 18 F-FDG PET in the diagnosis of Alzheimer's Disease.

Authors:  David P Nadebaum; Natasha Krishnadas; Aurora Mt Poon; Victor Kalff; Meir Lichtenstein; Victor L Villemagne; Gareth Jones; Christopher C Rowe
Journal:  Intern Med J       Date:  2020-05-10       Impact factor: 2.048

10.  Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease.

Authors:  I Zerr; K Kallenberg; D M Summers; C Romero; A Taratuto; U Heinemann; M Breithaupt; D Varges; B Meissner; A Ladogana; M Schuur; S Haik; S J Collins; Gerard H Jansen; G B Stokin; J Pimentel; E Hewer; D Collie; P Smith; H Roberts; J P Brandel; C van Duijn; M Pocchiari; C Begue; P Cras; R G Will; P Sanchez-Juan
Journal:  Brain       Date:  2009-09-22       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.